“The first vaccine for malaria, the mosquito-borne disease that kills 400 000 people each year, is set to be

deployed more widely after more than three decades of work and about $1-bn (about R15-bn) in

investment,” reported Bloomberg News (7 October 2021). The vaccine,

A study of 6 000 children, published in August, found that the combination of antimalarial drugs and vaccination (developed by GlaxoSmithKline) lowered hospitalisations and deaths from the disease by about 70% after three years.

A shot developed for the disease at the UK’s University of Oxford earlier this year became the first to meet a WHO goal of more than 75% efficacy in a mid-stage study.

BioNTech, meanwhile, is seeking to follow its successful Covid-19 vaccine with one to prevent malaria.


Other news